Cubist Pharmaceuticals (CBST) 101.94 $CBST
Cubist Pharmaceuticals Shares Up 52.7% Since SmarTrend's Buy Recommendation (CBST)
Comtex SmarTrend(R) - Wed Mar 25, 9:59AM CDT
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 5 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
52.7% Return Seen to Date on SmarTrend Cubist Pharmaceuticals Call (CBST)
Comtex SmarTrend(R) - Tue Mar 10, 5:08PM CDT
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 5 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
Cubist Pharmaceuticals Has Returned 52.7% Since SmarTrend Recommendation (CBST)
Comtex SmarTrend(R) - Mon Feb 09, 11:06AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 4 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
Uptrend Call Working As Cubist Pharmaceuticals Stock Rises 52.7% (CBST)
Comtex SmarTrend(R) - Mon Feb 02, 9:48AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 3 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
Merck concludes tender offer to acquire Cubist at USD102.00 per share
M2 - Thu Jan 22, 5:34AM CST
Healthcare company Merck (NYSE:MRK) said on Wednesday that it has acquired all of the outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST) at a purchase price of USD102.00 per share in a tender offer.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37)
Merck Completes Tender Offer to Acquire Cubist
BusinessWire - Wed Jan 21, 7:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7 percent of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37)
Dana Holding Set to Join the S&P MidCap 400
PR Newswire - Tue Jan 20, 4:45PM CST
Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent Merck & Co. Inc. (NYSE: MRK) is acquiring Cubist Pharmaceuticals in a transaction expected to be completed soon, pending final conditions.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37), DAN: 11.98 (-0.23), MHFI: 107.92 (+1.16)
Merck Speeds Up Lung Cancer, HCV Drugs; Filings in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:10PM CST
Merck (MRK) will seek FDA approval for its combination HCV treatment in the first half of this year and clearance to expand the use of Keytruda in lung cancer patients.
CBST: 101.94 (+0.14), MRK: 56.81 (-0.37), BMY: 72.65 (-0.08)
United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 85.70 (-0.08), UTHR: 111.35 (-1.78)
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 84.45 (-1.32), VNDA: 10.81 (-0.17), IMGN: 4.96 (-0.11), EXEL: 7.38 (+0.01)
Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:00PM CST
Spectrum Pharmaceuticals (SPPI) submitted a new drug application to the FDA for Captisol-enabled melphalan (propylene glycol-free) for the multiple myeloma transplant setting.
CBST: 101.94 (+0.14), LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03), BIOD: 0.34 (unch)
Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:10AM CST
Shares of Tetraphase Pharmaceuticals, Inc. have been riding high after the company announced positive top-line data from a phase III study evaluating its experimental antibiotic, eravacycline.
TTPH: 3.94 (-0.17), JNJ: 117.01 (+0.01), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37)
Cubist Pharmaceuticals Shares Up 52.7% Since SmarTrend's Buy Recommendation (CBST)
Comtex SmarTrend(R) - Wed Mar 25, 9:59AM CDT
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 5 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
52.7% Return Seen to Date on SmarTrend Cubist Pharmaceuticals Call (CBST)
Comtex SmarTrend(R) - Tue Mar 10, 5:08PM CDT
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 5 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
Cubist Pharmaceuticals Has Returned 52.7% Since SmarTrend Recommendation (CBST)
Comtex SmarTrend(R) - Mon Feb 09, 11:06AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 4 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
Uptrend Call Working As Cubist Pharmaceuticals Stock Rises 52.7% (CBST)
Comtex SmarTrend(R) - Mon Feb 02, 9:48AM CST
SmarTrend identified an Uptrend for Cubist Pharmaceuticals (NASDAQ:CBST) on October 21st, 2014 at $66.76. In approximately 3 months, Cubist Pharmaceuticals has returned 52.71% as of today's recent price of $101.94.
CBST: 101.94 (+0.14)
Merck concludes tender offer to acquire Cubist at USD102.00 per share
M2 - Thu Jan 22, 5:34AM CST
Healthcare company Merck (NYSE:MRK) said on Wednesday that it has acquired all of the outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST) at a purchase price of USD102.00 per share in a tender offer.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37)
Merck Completes Tender Offer to Acquire Cubist
BusinessWire - Wed Jan 21, 7:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7 percent of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37)
Dana Holding Set to Join the S&P MidCap 400
PR Newswire - Tue Jan 20, 4:45PM CST
Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent Merck & Co. Inc. (NYSE: MRK) is acquiring Cubist Pharmaceuticals in a transaction expected to be completed soon, pending final conditions.
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37), DAN: 11.98 (-0.23), MHFI: 107.92 (+1.16)
Merck Speeds Up Lung Cancer, HCV Drugs; Filings in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:10PM CST
Merck (MRK) will seek FDA approval for its combination HCV treatment in the first half of this year and clearance to expand the use of Keytruda in lung cancer patients.
CBST: 101.94 (+0.14), MRK: 56.81 (-0.37), BMY: 72.65 (-0.08)
United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 85.70 (-0.08), UTHR: 111.35 (-1.78)
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma
PR Newswire - Tue Dec 30, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (unch), CBST: 101.94 (+0.14), GILD: 84.45 (-1.32), VNDA: 10.81 (-0.17), IMGN: 4.96 (-0.11), EXEL: 7.38 (+0.01)
Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:00PM CST
Spectrum Pharmaceuticals (SPPI) submitted a new drug application to the FDA for Captisol-enabled melphalan (propylene glycol-free) for the multiple myeloma transplant setting.
CBST: 101.94 (+0.14), LGND: 113.74 (-1.34), SPPI: 6.94 (-0.03), BIOD: 0.34 (unch)
Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 11:10AM CST
Shares of Tetraphase Pharmaceuticals, Inc. have been riding high after the company announced positive top-line data from a phase III study evaluating its experimental antibiotic, eravacycline.
TTPH: 3.94 (-0.17), JNJ: 117.01 (+0.01), CBST: 101.94 (+0.14), MRK: 56.81 (-0.37)
